1. Home
  2. GABC vs NUVB Comparison

GABC vs NUVB Comparison

Compare GABC & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo German American Bancorp Inc.

GABC

German American Bancorp Inc.

HOLD

Current Price

$49.77

Market Cap

1.9B

Sector

Finance

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$5.73

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GABC
NUVB
Founded
1910
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.0B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
GABC
NUVB
Price
$49.77
$5.73
Analyst Decision
Buy
Strong Buy
Analyst Count
3
8
Target Price
$47.67
$11.38
AVG Volume (30 Days)
94.6K
4.6M
Earning Date
04-27-2026
05-04-2026
Dividend Yield
2.88%
N/A
EPS Growth
8.13
71.56
EPS
1.90
N/A
Revenue
$487,401,000.00
$62,902,000.00
Revenue This Year
$16.78
$203.82
Revenue Next Year
$3.98
$58.18
P/E Ratio
$26.18
N/A
Revenue Growth
37.80
698.96
52 Week Low
$37.19
$3.00
52 Week High
$52.23
$9.75

Technical Indicators

Market Signals
Indicator
GABC
NUVB
Relative Strength Index (RSI) 52.41 37.92
Support Level $48.85 $5.28
Resistance Level $51.97 $6.25
Average True Range (ATR) 0.80 0.29
MACD -0.05 -0.12
Stochastic Oscillator 69.15 12.06

Price Performance

Historical Comparison
GABC
NUVB

About GABC German American Bancorp Inc.

German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: